Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, is produced predominantly in the stomach. It has been reported that endogenous ghrelin levels are increased by fasting and decreased immediately after feeding and that fasting-induced ghrelin release is controlled by the sympathetic nervous system. However, the mechanisms of plasma ghrelin decrement after feeding are poorly understood. Here, we studied the control of ghrelin secretion using ghrelin-producing cell lines and found that these cells express high levels of mRNA encoding G-protein coupled receptor 120 (GPR120). Addition of GW-9508 (a GPR120 chemical agonist) and ␣-linolenic acid (a natural ligand for GPR120) inhibited the secretion of ghrelin by ϳ50 and 70%, respectively. However, the expression levels of preproghrelin and ghrelin O-acyltransferase (GOAT) mRNAs were not influenced by GW-9508. In contrast, the expression levels of prohormone convertase 1 were decreased significantly by GW-9508 incubation. Moreover, we observed that the inhibitory effect of GW-9508 on ghrelin secretion was blocked by a small interfering RNA (siRNA) targeting the sequence of GPR120. Furthermore, pretreatment with GW-9508 blocked the effect of the norepinephrine (NE)-induced ghrelin elevation in ghrelin cell lines. In addition, we showed that GW-9508 inhibited ghrelin secretion via extracellular signal-regulated kinase activity in ghrelin cell lines. Finally, we found that GW-9508 decreased plasma ghrelin levels in mice. These results suggest that the decrease of ghrelin secretion after feeding is induced partially by long-chain fatty acids that act directly on gastric GPR120-expressing ghrelin cells.
GHRELIN, A 28-AMINO ACID PEPTIDE with an n-octanoyl modification on the third amino acid, was purified as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) (15) . Ghrelin was first shown to stimulate growth hormone release from the anterior pituitary gland in vivo and in vitro (15, 33) and was later found to be deeply involved in the regulation of feeding behavior and energy homeostasis (20, 27, 30, 32) . In addition to these physiological functions, ghrelin has been shown to play several roles in the stimulation of gastric motility, cell proliferation, mood, and torpor (1, 3, 6, 10, 14, 19) . The binding of ghrelin to its specific receptor, GHS-R, and its biological activity are entirely dependent on the attachment of octanoate to the third serine residue, a reaction catalyzed by ghrelin O-acyltransferase (GOAT) (34) .
As reported, ghrelin cells are classified into open-and closed-type cells and localized to the mucosa of the stomach, duodenum, ileum, cecum, and colon but not to the myenteric plexus (23) . The greatest number of ghrelin cells was found in the stomach; these are small, round, closed-type cells known as X/A-like cells. In addition, the number of the open-type cells was shown to gradually increase in the direction from the stomach to the lower gastrointestinal tract (23) . The reduction of plasma ghrelin concentration after gastrectomy has been reported, with a nadir ghrelin level of 28.6 Ϯ 11.1% at 1 h after gastric resection that remained at 30.0 Ϯ 13.2% for 7 days postoperatively (13) . These reports suggest that a major source of plasma ghrelin is the stomach mucosal layer.
It has been reported that the normal plasma ghrelin concentration was 10 -20 fmol/ml for n-octanoyl ghrelin and 100 -150 fmol/ml for total ghrelin, including both acyl-and des-acyl ghrelins (25) , and that plasma ghrelin concentration rises dramatically before each meal and declines immediately after feeding commences in humans (4, 21) . In some physiological or pathophysiological states, circulating ghrelin levels are characteristically changed. For example, plasma ghrelin concentrations are high during fasting, calorie restriction, and stress in humans and rodents (16, 17) . On the other hand, plasma ghrelin levels are low in obese and diabetic animals and humans (22, 31) . In addition, ghrelin levels have been reported to be affected in several gastrointestinal diseases/disorders such as inflammatory bowel disease, infectious diseases, functional disorders, and diabetes gastroenteropathy (5) .
In contrast to the action of ghrelin, the regulatory mechanisms of ghrelin secretion are not fully understood. Stimulation of ghrelin secretion has been shown via the sympathetic nervous system through the ␤ 1 -adrenergic receptor expressed in ghrelin cells (35) . However, the factors and detailed mechanisms for the inhibition of ghrelin secretion after feeding have not yet been fully identified. High blood glucose levels following oral and intravenous administration of glucose were reported to decrease ghrelin concentration (26) . In addition, we showed that high glucose inhibited ghrelin secretion in primary cultures of gastric mucosal cells (24) . Thus, we expected glucose as well as fatty acids that are absorbed from the foods to be involved in the inhibition of ghrelin secretion. In this study, we examined the in vitro effect of long-chain fatty acids (LCFA) on ghrelin secretion using ghrelin cell lines established from the stomach and the in vivo effect using mice as well as the underlying signaling transduction pathways involved in ghrelin secretion.
MATERIALS AND METHODS
Cell lines and animals. The stomach ghrelinoma cell (SG-1) line was generated using mice expressing SV40 T-antigen, as described previously (35) . SG-1 cells were cultured in DMEM-F-12 50:50 (Cellgro, Manassas, VA) containing 10% fetal bovine serum and supplemented with penicillin (100 U/ml) and streptomycin (100 g/ml) in a 37°C incubator with 5% CO 2 and 5% O2. Male C57BL/6J wild-type mice (Nihonikagaku, Tokyo, Japan) between 9 and 11 wk of age were used for the experiments. The animals were housed individually in plastic cages with ad libitum access to food and drinking water. The animal room was maintained at 21-24°C on a 12:12-h light-dark cycle (lights on from 0800 to 2000). All procedures were approved and performed in accordance with the guidelines of the Saitama University Committee on Animal Research and the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee. All efforts were made to minimize animal suffering and to reduce the number of animals used in the experiment.
Chemicals. GW-9508, ␣-linolenic acid (␣-LA), DL-norepinephrine hydrochloride, H-89, and U-0126 were purchased from Sigma (St. Louis, MO). Sodium octanoate was purchased from Wako (Osaka, Japan). G-protein coupled receptor 120 (GPR120) small interfering RNA (siRNA) and GPR40 siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
RT-PCR. Total RNA from SG-1 cells and white adipose, pancreatic, and stomach tissues was extracted using ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. For GPR120 experiments, trace DNA contamination was removed by DNase digestion (Promega, Madison, WI), and cDNA was synthesized from 1 g of DNase-treated total RNA using ReverTra Ace (Toyobo, Osaka, Japan) and random primers (no. 48190-011; Invitrogen, Carlsbad, CA). For GPR40 experiments, poly(A) RNA was extracted from the total RNA by a poly(A) RNA isolation kit (Nippon Gene), and cDNA was synthesized from 100 ng of poly(A) RNA using ThermoScript RT (Invitrogen) and random primers. We used 100 ng of poly(A) RNA not subjected to reverse transcription as a negative control. The following primers were designed to amplify mouse GPR120 (fragment size: 118 bp): sense primer, 5=-CCCAAC-CGCATAGGAGAAAT-3=; antisense primer, 5=-GCGATGCTTT-CGTGATCTGT-3=. The following primers were designed to amplify mouse GPR40 (fragment size: 391 bp): sense primer, 5=-GACT-CACTCCCAGCTTGGTC-3=; antisense primer, 5=-GAGCCATTC-ACGGGTATGTT-3=. The following primers were used to amplify mouse ␤-actin as an internal control (fragment size: 210 bp): sense primer, 5=-CTGGGTATGGAATCCTGTGG-3=; antisense primer, 5=-GTACTTGCGCTCAGGAGGAG-3=. Reactions were performed using an iCycler thermocycler (Bio-Rad, Hercules, CA). For GPR120 and ␤-actin, the cycle profile was programmed as follows: 10 min at 30°C, 20 min at 42°C, and 5 min at 99°C (reverse transcription); 5 min at 94°C (initial PCR activation); and 40 cycles of 30 s at 94°C (denaturation), 30 s at 60°C (annealing), and 30 s at 72°C (extension). The final extension step was extended to 5 min at 72°C. For GPR40, the cycle profile was programmed as follows: 10 min at 25°C, 50 min at 55°C, and 5 min at 85°C (reverse transcription); 5 min at 94°C (initial PCR activation); and 40 cycles of 40 s at 94°C (denaturation), 40 s at 62°C (annealing), and 40 s at 72°C (extension). The final extension step was extended to 5 min at 72°C. The amplicon size and specificity were confirmed by 2% agarose gel electrophoresis.
Ghrelin secretion experiment. On day 0 at 1800, SG-1 cells were plated at a concentration of 1 ϫ 10 6 cells/well in 12-well plates with DMEM-F-12 50:50 containing 10% fetal bovine serum and supplemented with penicillin (100 U/ml) and streptomycin (100 g/ml) containing 50 M sodium octanoate. On day 2 at 1000, the medium was aspirated before 400 l of serum-free 5 mM D-glucose-DMEM (Gibco, Tokyo, Japan) containing 50 M sodium octanoate with chemicals was added. After incubation at 37°C for 3 [␣-linolenic acid, 10 M norepinephrine (NE) with 10 M H-89, or 100 M GW-9508 with 10 M U-0126] or 6 h (GW-9508), the medium was collected and centrifuged at 3,000 rpm for 5 min at 4°C. Next, 100 l of supernatant was transferred to a separate tube, and 10 l of 1 N HCl was added immediately to the tube. To measure cellular ghrelin content, SG-1 cells were collected and centrifuged at 1,200 rpm for 5 min at 4°C. The pellet was washed twice with cold phosphatebuffered saline (PBS), and then 0.2 ml of RIPA buffer containing 1ϫ protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) was added; the mixture was placed on ice for 30 min and homogenized every 5 min during incubation. The cell lysate was centrifuged at 12,000 g for 10 min at 4°C. Next, 100 l of supernatant was transferred to a separate tube, and 10 l of 1 N HCl was added immediately to the tube. The samples were stored at Ϫ80°C until analysis. Acyl-ghrelin concentrations were determined using a rat acylated ghrelin enzyme immunoassay kit (Bertin Pharma, Montigny le Bretonneux, France) according to the manufacturer's guidelines.
Quantitative RT-PCR. On day 0 at 1000, SG-1 cells were plated in 12-well plates at a concentration of 1 ϫ 10 6 cells/well in DMEM-F-12 50:50 containing 10% fetal bovine serum, supplemented with penicillin (100 U/ml) and streptomycin (100 g/ml) containing 50 M sodium octanoate, and treated with 30 M or 100 M GW-9508 for 24 or 48 h. On days 1 and 2 at 1000, the medium was aspirated, and the cells were washed once with PBS before RNA was extracted using ISOGEN (Nippon Gene). We used 1 g of RNA for the synthesis of cDNA using ReverTra Ace quantitative RT-PCR kit (Toyobo, Osaka, Japan). Real-time PCR was completed using LightCycler (Roche Diagnostics) with SYBR premix Ex Taq (Takara Bio, Shiga, Japan) with the following primers: for mouse preproghrelin, forward 5=-CCCAGGCATTCCAGGTCAT-3=, reverse 5=-AACTGCAGATG-GTGCCTGAAG-3=; for mouse GOAT, forward 5=-TCCACAGC-CTGGCTCTTTAAAC-3=, reverse 5=-GCCGCGTGGAGGAGAGA-3=; for mouse prohormone convertase 1 (PC1), forward 5=-GGCA-CCTGGACATTGAAAATTAC-3=, reverse 5=-TTCATGTGCTCTG-GTTGAGAAGA-3=; for mouse prohormone convertase 2 (PC2), forward 5=-CAGATTTAGCATCAAGCACA-3=, reverse 5=-AAAC-
P a n c r e a s S G 1 D W S t o m a c h Fig. 1 . G protein-coupled receptor 120 (GPR120) and GPR40 mRNA expression within stomach ghrelinoma (SG-1) cells. PCR products and specificity were confirmed by 2% agarose gel electrophoresis. GPR120 was expressed in SG-1 cells, gastric tissue, and white adipose tissue (positive control). Although GPR40 was expressed on gastric tissue and pancreatic tissue (positive control), GPR40 mRNA was not expressed in SG-1 cells. Distilled water (DW) was used as negative control, and ␤-actin was used as an internal control.
CATCACACAGAAGAGG-3=; and for mouse cyclophilin, forward 5=-TGGAGAGCACCAAGACAGACA-3=, reverse 5=-TGCCGGAG-TCGACAATGAT-3=. The initial template denaturation was programmed for 30 s at 95°C, and PCR was performed with 40 cycles of 5 s at 95°C and 30 s at 60°C. Mouse cyclophilin mRNA was used as the invariant control. The expression of each mRNA is shown relative to cyclophilin mRNA expression. All reactions were performed in duplicate.
Western blotting. SG-1 cells from four different groups were collected and centrifuged at 1,200 rpm for 5 min at 4°C. Next, the supernatant was used as the medium sample. The pellet was washed twice with cold PBS, and then 0.2 ml of RIPA buffer, including 1ϫ phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan), was added, and the sample was placed on ice for 30 min and homogenized every 5 min during incubation. The cell lysate was centrifuged at 12,000 g for 10 min at 4°C, after which the supernatant was collected. Total protein concentrations were measured using a BCATM Protein Assay kit (Thermo Fisher, Waltham, MA) according to the manufacturer's instructions. Equal amounts of protein (20 g) were run on 12% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and electroblotted onto PVDF membranes. The membranes were probed successively with primary anti-mouse phosphorylated p44/42 MAPK (ERK1/2) (Thr 202 /Tyr 204 ) (no. 9101; Cell Signaling Technology, Danvers, MA) diluted 1:1,000 and primary anti-mouse p44/42 MAPK (Erk1/2) (no. 9102; Cell Signaling Technology) diluted 1:1,000, followed by probing with horseradish peroxidase (HRP)-labeled secondary antibody (Promega, Madison, WI) diluted 1:50,000. Specific antigen-antibody binding was visualized using Luminata Forta Western HRP substrate (Millipore, Billerica, MA). Images were analyzed using Image J software (National Institutes of Health, Bethesda, MD). GPR120 siRNA experiment. A pool of three 19-to 25-nucleotide (nt) siRNAs targeting the mRNA sequence of GPR120 was purchased from Santa Cruz Biotechnology. A pool of two 19-to 25-nt siRNAs targeting the sequence of GPR40 was used as a negative control. On day 0 at 1000, SG-1 cells were plated at a concentration of 1.5 ϫ 10 5 cells/well in 12-well plates with DMEM-F-12 50:50 containing 10% fetal bovine serum and supplemented with 50 M sodium octanoate. On day 1 at 1000, transfection of siRNA (50 nM) was accomplished with Lipofectamine 2000 (Invitrogen). After 48 h, cells were stimulated for 6 h with vehicle or GW-9508 (100 M), after which the culture medium was processed as described above. Total RNA was extracted from the cells to quantify the relative expression level of GPR120 by RT-PCR. Images were analyzed by Image J software.
In vivo experiments. Ten mice were divided into two groups and administered either vehicle or GW-9508. On day 1 at 1700, blood was taken from a caudal vein before GW-9508 (2.1 g/g body wt) or DMSO (0.1% vol/vol) diluted in saline was injected subcutaneously at a volume of 150 l/mouse. Mice were fasted for 24 h. On day 2, blood was again taken from a caudal vein. Blood was collected in the presence of 0.5 M EDTA, pH 8.0 (Gibco), and 1 mM parahydroxymercuribenzoate (Sigma) to prevent the degradation of acylated ghrelin. Blood was centrifuged at 3,500 rpm for 10 min at 4°C before the supernatant was transferred to a separate tube, and 1 N HCl (10% vol/vol of total plasma) was added. Samples were stored at Ϫ80°C until analysis. All experiments were conducted in a crossover manner at 14-day intervals, during which time all animals received DMSO or GW-9508 injection on separate days.
Statistical analysis. All data were expressed as means Ϯ SE, and statistical analyses were performed using GraphPad Prism 5 Software (GraphPad Software, La Jolla, CA). In vitro data were standardized to A: a representative gel showed that GPR120 small interfering RNA (siRNA) decreased the expression levels of GRP120. B: GPR120 siRNA significantly decreased the mRNA expression level to ϳ50%. C: as a negative control, GPR40 siRNA did not influence the effect of GW-9508 on acyl-ghrelin secretion. However, by knocking down the expression level of GPR120, GW-9508-induced inhibition of acyl-ghrelin secretion was markedly reversed. Data are presented as means Ϯ SE; n ϭ 6. **P Ͻ 0.001; ***P Ͻ 0.0001. 
RESULTS

GPR120/GPR40 mRNA expression and the effect of GPR120 ligands on ghrelin secretion in SG-1 cells.
GPR120 and GPR40 mRNA transcripts were detected in whole stomach tissue; however, GPR40 mRNA was not found in SG-1 cells. In contrast, GPR120 mRNA was strongly expressed in SG-1 cells (Fig. 1) . In a previous study, we performed a gene chip array using primary gastric ghrelin-producing cells from ghrelin-GFP transgenic mice (31a), and we found that GPR120 mRNA was expressed at higher levels in ghrelin-producing cells than in other gastric mucosal cells (data not shown).
To determine the role of GPR120 on ghrelin secretion, GW-9508, a chemical agonist, was added to the medium. GW-9508 significantly inhibited the acyl-ghrelin secretion in the medium (60% of control with 30 M GW-9508, 50% of control with 100 M GW-9508; Fig. 2A ). In addition, ␣-LA, a natural ligand, significantly suppressed ghrelin secretion in a dose-dependent manner (55% of control with 100 M ␣-LA, 30% of control with 300 M ␣-LA; Fig. 2B ). In addition, GW-9508 significantly decreased cellular ghrelin concentration (Fig. 2C) .
Preproghrelin and GOAT mRNA expression was examined after 24 and 48 h incubation with GW-9508. Quantitative PCR showed that preproghrelin and GOAT mRNA levels were not altered by GW-9508 (30 and 100 M) treatment in either incubation period (Figs. 2D and 3A) and that PC1 mRNA levels were significantly decreased after 24 and 48 h of incubation with GW-9508 (Fig. 3B) . In contrast, PC2 mRNA was increased at 24 h of incubation with GW-9508 (Fig. 3C) . A: H-89 blocked nearly all NE-induced ghrelin secretion. The inhibitory effect of GW-9508 on ghrelin secretion was determined in the presence of U-0126. B: U-0126 significantly reversed GW-9508-inhibited ghrelin secretion. C: phosphorylation levels of ERK were measured by Western blotting after GW-9508 and U-0126 treatment. GW-9508 increased the phosphorylation levels of ERK, whereas coadministration of GW-9508 with U-0126 returned the phosphorylation levels of ERK to control levels. D: GW-9508 significantly increased the ratio of p-ERK with ERK, whereas U-0126 significantly reversed GW-9508-induced ERK phosphorylation. E: subsequently, 30 and 100 M GW-9508 were used for pretreatment for 1 h before NE (10 M) stimulation. GW-9508 almost completely blocked the NE-induced ghrelin elevation. Data are presented as means Ϯ SE; n ϭ 6. *P Ͻ 0.05; **P Ͻ 0.001; ***P Ͻ 0.0001.
Next, we examined the effect of GPR120 siRNA knockdown on ghrelin secretion in SG-1 cells. Incubation with GPR120 siRNA for 48 h decreased the mRNA expression levels to ϳ50% compared with that in the control group, and the inhibitory effect of GW-9508 on ghrelin secretion was completely reversed in GPR120 siRNA-treated SG-1 cells. However, GPR40 siRNA did not change GW-9508-induced ghrelin inhibition (Fig. 4, A-C) .
Intracellular signaling of ghrelin secretion. To determine the intracellular signaling pathway of ghrelin secretion, several pathway inhibitors were used in SG-1 cell cultures. The stimulatory effect of NE-induced ghrelin secretion was blocked by coadministration with H-89, a PKA inhibitor (Fig. 5A) . U-0126, an ERK inhibitor, was used to identify the signaling pathway that regulates GW-9508-mediated inhibition of acylghrelin secretion. Coadministration of GW-9508 with U-0126 significantly reversed GW-9508-induced acyl-ghrelin inhibition (Fig. 5B) . In addition to U-0126, three other intracellular signaling inhibitors, H-89, PD-98059 (another ERK inhibitor), and wortmannin [a phosphoinositide 3-kinase (PI3K) inhibitor], were used. Coadministration of GW-9508 with H-89 or wortmannin did not reverse GW-9508-mediated inhibition of acyl-ghrelin secretion. However, coadministration of GW-9508 with PD-98059 significantly reversed GW-9508-induced acyl-ghrelin inhibition (data not shown). GW-9508 increased phosphorylation levels of ERK, whereas coadministration of GW-9508 with U-0126 returned the phosphorylation levels of ERK to those of control levels (Fig. 5C ). GW-9508 significantly increased the ratio of p-ERK/ERK, whereas U-0126 significantly reversed the GW-9508-induced ERK phosphorylation (Fig. 5D) .
Effect of GPR120 signaling on NE-induced ghrelin elevation. To test the effect of GPR120 signaling on NEinduced ghrelin elevation, cells were pretreated with GW-9508 at a concentration of 30 or 100 M for 1 h before NE stimulation. NE (10 M) increased the acyl-ghrelin secretion (2.5 times of vehicle). Pretreatment with 30 and 100 M GW-9508 significantly blocked NE-induced acyl-ghrelin secretion (Fig. 5E) .
Effect of GW-9508 on the plasma acyl-ghrelin level in mice. We next sought to determine whether GPR120 is important in the in vivo regulation of acyl-ghrelin secretion in the mouse. The concentration of plasma acyl-ghrelin was elevated after 24 h of fasting in the control group. However, GW-9508 administration significantly blocked fasting-induced acyl-ghrelin elevation in mice (a decrease of nearly 50% of that observed in the control group; Fig. 6 ).
DISCUSSION
It has been reported that plasma ghrelin levels rise 1-2 h before each meal and fall immediately after feeding and that this transient surge can be modified by the feeding regimen in sheep (28) . NE has been reported to stimulate ghrelin secretion through the ␤ 1 -adrenergic receptors that are expressed on ghrelin cells, suggesting that NE released from sympathetic nerve terminals directly regulates ghrelin secretion. Nutrients such as carbohydrates, protein, and fatty acids have been considered as possible factors that inhibit ghrelin secretion after feeding. Actually, oral glucose load decreases plasma ghrelin concentration in humans and rats (26) . Recently, it has been shown that ghrelin levels of primary gastric mucosal cells are low when cultured in medium containing 10 mM glucose, which is equivalent to a high blood glucose level (180 mg/dl). In contrast, when glucose levels are decreased to 1 mM (equivalent to a blood glucose level of 18 mg/dl), ghrelin release is enhanced. This suggests that ghrelin-producing cells directly sense plasma glucose levels. In this study, we hypothesized that fatty acids would be involved in the inhibition of ghrelin secretion after feeding and focused on GPR120 because of its regulatory control over the secretion of other hormones such as insulin, glucagon-like peptide-1 (GLP-1), and CCK, which are influenced dramatically by feeding (11, 29) .
Because ghrelin-producing cells make up only a tiny fraction of cells in the gastric mucosa, elucidation of the molecular mechanisms that control ghrelin secretion has been hampered. In the present study, we used a ghrelin-producing cell line, SG-1, which was derived from mice bearing a ghrelinoma induced by a tissue-specific SV40 T-antigen transgene. SG-1 cells were enriched in the mRNA transcripts encoding preproghrelin and GOAT, and the cultured SG-1 cells required exogenous octanoate to secrete appreciable amounts of acylghrelin (35) . We found that these cells were also enriched in the mRNA encoding GPR120. After incubation with GW-9508 and ␣-LA, the secretion of acyl-ghrelin was significantly inhibited. GPR40 mRNA was not expressed in SG-1 cells, although GW-9508 and ␣-LA, which are GPR120 ligands, also activate GPR40. In addition, we found that the inhibitory effect of GW-9508 was blocked by the knockdown of GPR120 by siRNA. These results suggest that LCFAs from circulation are involved in the regulation of ghrelin secretion through GPR120 on the ghrelin cells. On the other hand, administration of GW-9508 did not change preproghrelin or GOAT mRNA expression, indicating that GPR120 regulates ghrelin secretion but does not affect ghrelin and GOAT mRNA transcriptions. However, the expression level of PC1 was inhibited by GW-9508. We also found that GW-9508 decreased acyl-ghrelin content within the cells. Previously, Zhu et al. (36) reported that PC1/3 but not PC2 is responsible for the protease processing of proghrelin to the 28-amino acid ghrelin. Taken together, these results suggest that PC1 levels regulate ghrelin secretion and that PC2 is involved in the processing of other peptides produced in ghrelin cells. GW-9508 (2.1 g/g body wt) or vehicle was injected before 24-h fasting, and blood was taken from caudal vein for measurement of plasma ghrelin concentrations. Fasting-induced ghrelin elevation in the control mice; however, GW-9508 partially blocked the fasting-induced ghrelin secretion. Data are presented as means Ϯ SE; n ϭ 5. ***P Ͻ 0.0001.
Next, we hypothesized that postfeeding decrease in ghrelin levels is caused partially by the recognition of LCFA by GPR120. As expected, we found that a GPR120 agonist decreased the fasting-induced plasma acyl-ghrelin elevation in vivo when compared with that in the control mice, indicating that GPR120 is physiologically important for the homeostasis of ghrelin levels. Our current findings are in agreement with those recently found by Lu et al. (18) . In particular, Lu et al. (18) had shown GPR120 to be expressed in FACS-separated gastric ghrelin cells from a novel ghrelin-GFP transgenic mouse model, LCFA, to inhibit ghrelin secretion from those cells in vitro and LCFA-rich lipid delivery to mice with pylorus ligation via gavage to decrease serum ghrelin levels in vivo (18) . Janssen et al. (12) also revealed that ␣-LA inhibited ghrelin secretion from an MGN3-1 ghrelinoma cell line. However, they showed that grifolic acid (a GPR120-selective partial agonist) did not inhibit ghrelin secretion from MGN3-1 cell lines and increased plasma ghrelin levels in vivo. These conflicting results might be due to different ghrelin-producing cell lines and chemical agonists used and/or different experimental design, duration of fasting period, or treatment period with agonist.
The ERK/MAPK pathway plays an essential role in connecting cellular surface receptors to nuclear transcriptional changes and is involved in many physiological processes, including cell proliferation, differentiation, migration, apoptosis, metabolism, and gene regulation (2, 8, 9) . Recently, GPR120 was reported to regulate GLP-1 secretion through the ERK pathway (11) . Thus, we focused on the relationship between the ERK pathway and GRP120-mediated suppression of ghrelin secretion and found that both of the ERK/MAPK pathway inhibitors significantly reversed GW-9508-inhibited ghrelin secretion. In addition, GW-9508 significantly increased phosphorylation levels of ERK. However, neither a PKA pathway inhibitor nor a PI3K pathway inhibitor showed an effect. These results suggest that GPR120 signaling for ghrelin secretion is mediated by the ERK/MAPK pathway. This pathway is known to have stimulatory functions on cell biological activities; however, our study showed that the ERK/MAPK pathway also played some inhibitory roles. In addition, NE has been reported to stimulate ghrelin secretion via the PKA pathway (7). Moreover, NE-induced ghrelin secretion was blocked by GW-9508, suggesting that there may be cross-talk between GPR120 signaling and the NE signaling pathway, which may control the homeostasis of ghrelin secretion under fasting and feeding conditions.
In summary, GPR120 mRNA was expressed in the ghrelinproducing SG-1 cells, and its ligands significantly inhibited ghrelin secretion in vitro. This inhibition was reversed by the knockdown of GPR120. Moreover, a GPR120 agonist prevented fasting-induced plasma ghrelin elevation in vivo. In addition, we found that GPR120 inhibited ghrelin secretion via the ERK/MAPK pathway. These results suggest that the decrease in plasma ghrelin levels after feeding is controlled partially by the recognition of LCFA by GPR120.
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